Combined inhibition of BCL2 activity and CD28 signaling to prevent graft-versus-host disease
Post-transplantation cyclophosphamide (PTCy)-based prophylaxis has become one of the most widely used strategies to prevent graft-versus-host disease (GVHD), particularly after HLA-haploidentical hematopoietic cell transplantation (HCT). Well-tolerated GVHD prophylaxis regimens beyond PTCy are needed, because adverse events associated with Cy administration, such as cardiac toxicity, remain a safety concern. Costimulation blockade using abatacept (ABA) is an established complementary strategy to improve GVHD prevention without a calcineurin inhibitor. Here, we investigated venetoclax (VEN), a selective B-cell leukemia/lymphoma 2 (BCL-2) inhibitor, as a candidate partner with ABA to prevent GVHD. In a murine MHC-haploidentical HCT model, we demonstrate that prevention of GVHD with a combination of short-term VEN and CD28 costimulation blockade using ABA (VEN+ABA) was comparable to that with Cy+ABA and superior to that with Cy monotherapy, while maintaining GVL effects. Flow cytometry analysis revealed a higher regulatory T (Treg)/conventional T (Tcon) ratio with the VEN+ABA combination compared to Cy+ABA. Using donor CD8+ alloreactive TCR-transgenic T cells, we show that the VEN+ABA combination produced a prominent cleaved caspase-3 signature only in allo-activated T cells, and cells from the spleen at day 9 after HCT with VEN+ABA did not respond after ex vivo CD3/CD28 stimulation. Collectively, our study supports a VEN+ABA GVHD prophylaxis strategy associated with preferential apoptosis of alloreactive T cells while preserving GVL activity to replace alkylator-based prophylaxis.
Authors
- Megumi Narisawa (ORCID: https://orcid.org/0009-0000-6581-4708)
- Atsushi Enomoto (ORCID: https://orcid.org/0000-0002-9206-6116)
- Hiroyoshi Nishikawa (ORCID: https://orcid.org/0000-0001-6563-9807)
- Akihiro Tomita (ORCID: https://orcid.org/0000-0002-5391-1399)
- Yasuhiro Maeda (ORCID: https://orcid.org/0000-0001-8327-5875)
- Sachiko Ito (ORCID: https://orcid.org/0000-0001-9313-7089)
- Yoshiki Akatsuka (ORCID: https://orcid.org/0000-0003-3623-2826)
- Yuki Miyai (ORCID: https://orcid.org/0000-0003-0386-1431)
- Qiuyu Zhao
- Carolyne Barakat
- Hao Chen
- Xin Lu
Institutions
- Fujita Health University (JP)
- Kyoto University (JP)
- National Cancer Centre Japan (JP)
- Nagoya University (JP)
Publication Details
- Journal
- Blood Advances
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1182/bloodadvances.2026021048
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00